Rare Interview with Moderna CEO Stephane Bancel in Davos in Jan. 2023. New mRNA Vaccines Coming
Doubling down on failed mRNA, intends to produce 1 billion mRNA doses
All Global Research articles can be read in 51 languages by activating the Translate Website button below the author’s name (desktop version)
To receive Global Research’s Daily Newsletter (selected articles), click here.
Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.
***
This is a rare interview with Moderna CEO Stephan Bancel that took place at the World Economic Forum (WEF) in Davos, Switzerland, in January 2023.
Big pharma is doubling down on failed mRNA technology. There have been significant efforts lately, to bring other mRNA products to market as soon as possible, before the public at large turns against the entire mRNA platform.
“We are working on a lot of vaccines, around 30+ vaccines today” – Stephane Bancel
There are currently three Moderna mRNA vaccines that are in Phase 3 trials: Influenza, RSV, CMV.
There are also several in Phase 2 trials: Zika virus, cardiac ischemia, and cancer.
mRNA RSV adult vaccine
This is the one the media are pushing heavily and may be the next one to hit the market in 2023:
“Moderna intends to submit for regulatory approval in the first half of 2023” (click here)
Several news reports have circulated in the last few weeks about a “3-in-1 Supershot” to combat “vaccine fatigue” which includes COVID-19, Influenza and RSV (click here). This is coming from Australian media.
In another WEF interview in Davos, Stephane Bancel claims that the RSV protein in Moderna’s mRNA RSV vaccine “doesn’t mutate as much as flu or COVID”.
He also claims that all Moderna products “use the same manufacturing process” as the COVID-19 mRNA vaccines, including “the same raw material…same lipid”, meaning lipid nanoparticle (LNP).
This is very important information, as the adverse events following COVID-19 vaccination have been linked not just to the SARS-CoV2 spike protein but the LNP delivery mechanism itself, which is highly inflammatory:
“The same dose of LNP delivered intranasally led to similar inflammatory responses in the lung and resulted in a high mortality rate, with mechanism unresolved.” (click here)
In January 2023, Moderna reported Phase 3 trial results in older adults with “83.7% efficacy”. Much more concerning is that “trials of the vaccine in pregnant women and infants are now underway” (click here).
mRNA CMV vaccine
This vaccine against cytomegalovirus is aimed at young healthy men and women of reproductive age (click here). I have seen no media push on this one yet.
mRNA cancer vaccines (melanoma)
This has been described as an extremely expensive personalized treatment for melanoma cancer patients:
“Moderna melanoma vaccine is tailor-made for each patient. Each tumor is unique, and so the vaccine needs to be unique as well. To customize vaccines, researchers first biopsy the patient’s tumor to determine what neoantigens are present. The vaccine manufacturer then designs specific mRNA molecules that encode those neoantigens. When this custom mRNA vaccine is administered, the body translates the genetic material into proteins specific to the patient’s tumor, resulting in an immune response against the tumor.” (click here)
Personalized cancer treatments are another money-making area that the Trudeau Liberal government has been investing heavily into (click here). This was the field of cancer treatments that I specialized in, before my Cancer program in Alberta was shut down and restarted in British Columbia.
This will be a multi-billion dollar industry in the future (click here):
“According to Precedence Research, the global nuclear medicine market size is expected to hit around USD 25.7 billion by 2030”.
mRNA cystic fibrosis in kids
This mRNA vaccine to treat cystic fibrosis in kids is inhaled:
“VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle. It is the result of a 6-year-old research collaboration with Moderna.” (click here).
Building a “global manufacturing network”
“We are building a plant as we speak in Canada, one in the UK, one in Australia, one in Kenya…so that in every continent we have plants and we have more capacity” – Stephane Bancel
“In 6 months to develop a vaccine which I think we can do next time…we can make a billion doses” – Stephane Bancel
This builds on my article about the mRNA mega-factory that is being built in a smart city in South Korea (click here).
The groundbreaking ceremony for the Canadian mRNA factory was held in November 2022 (click here):
My Take…
Billions of dollars are being invested into building mRNA factories all over the world. It will be interesting to monitor where these are being built.
I expect the media to continue pushing mRNA vaccines for RSV and influenza for the general population including pregnant women, while CMV will be pushed mainly for women of reproductive age, pregnant or not. The media will try to promote these vaccines as “safer” than the COVID-19 mRNA vaccines.
mRNA vaccines for cancers will be prohibitively expensive and will be reserved only for those who can afford them. All cancer treatments will be shifted towards “personalized cancer treatments”, as this is where the big money will be in the future.
Those who can afford these cancer treatments will live for a while, those who cannot, will be offered MAID (medical assistance in dying).
It is interesting to note that the highly inflammatory and toxic lipid nanoparticle (LNP) platform will be used for ALL of these mRNA vaccines, and as we saw with the COVID-19 mRNA vaccines, these LNPs will be delivered all over the body: the heart, the brain, liver, kidneys, testes, ovaries; they will continue to cause tremendous inflammation and internal damage.
Moderna has no intention to fix, or abandon the LNP delivery platform.
*
Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.
